The impact of EndoPredict ® on decision making with increasing oncological work experience: can overtreatment be avoided?
- 19 February 2019
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 299 (5) , 1437-1442
Abstract
Estimating distant recurrence risk in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer is still challenging. EndoPredict® is a gene expression-based test predicting the likelihood of recurrent disease. We analyzed the difference in oncological decision making with and without the knowledge of gene expression tests.Keywords
This publication has 22 references indexed in Scilit:
- The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER+/HER2− Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic IndexAnticancer Research, 2018
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018Breast Care, 2018
- Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancerPLOS ONE, 2017
- Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1PLOS ONE, 2017
- Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast CancerJournal of Clinical Oncology, 2015
- Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis testBMC Cancer, 2012
- Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assayVirchows Archiv, 2012
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals of Oncology, 2009
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Molecular portraits of human breast tumoursNature, 2000